Fujitsu Corporation

Bayer Aktiengesellschaft

Actimis Pharmaceuticals, Inc.

Axikin Pharmaceuticals, Inc.

Bayer Healthcare Aktiengesellschaft

Bayer Schering Pharma Ag

Takashi Yoshino

Takuya Shintani

Toshiki Murata

Kevin Bacon

Klaus Urbahns

Yuji Koriyama

Hiroki Sato

Timothy B Lowinger

Kinji Fuchikami

Kazuo Mineno

Tsutomu Masuda

Mitsuyuki Shimada

Karl Ziegelbauer

Hiromi Sugimoto

Hiroshi Komura

Keiko Fukushima

Masaomi Umeda

Sachiko Sakakibara

Noriko Nunami

Tai-wei Ly

Toshiya Moriwaki

Yingfu Li

Timothy Lowinger

Hiroshi Kadono

Norihiro Kawamura

Mitsuhiro Sato

Rolf Grosser

Nagahiro Yoshida

Kevin B Bacon

Hisashi Sugawara

Masaki Nagao

Naoki Omori

Megumi Yamauchi

Hiroko Yoshino

Kosuke Tao

Mami Miura

Kazuho Tanaka

Yoshihisa Manabe

Masanori Seki

Akihiko Watanabe

Tetsuo Kikuchi

Tai-Wei Ly

Kenichi Yamashita

Shinichiro Nishizawa

Yasushi Toriwaki

Keiko Ishii

Yuki Takekawa

Tsuyoshi Taneishi

Hideki Tsujishita

Sachiko Sasaki

Atsushi Wataki

Yuka Ikegami

Makoto Shimazaki

Makoto Omori

Satoko Matsukawa

Florian Gantner

Yoshino Hiroko

Information processing system includes a first certification device which executes a first temporary certification, creates a first temporary certificate, transmits it to an external device, carries out a first formal certification and creates the first formal certificate, a second certification device which executes a second temporary certification based on the first temporary certification, creates a second temporary certificate, transmits it to the external device, carries out a second formal certification and creates the second formal certificate, and a processing device which verifies a validity of the first formal certificate corresponding to the first temporary certificate and a validity of the second formal certificate corresponding to the second temporary certificate from the user, in response to a information processing request from the user and determines to execute the information processing corresponding to the information processing request based on the verification result.

Information processing system, information processing method and computer readable recording medium stored a program

A data converting apparatus includes a storage unit that stores encoded meta-definition information, a data converting function, a conversion rule table, and a conversion rule; an input unit that receives input of data to be converted; a detecting unit that uses the encoded meta-definition information to detect metadata codes for a conversion source and a conversion destination for which the conversion rule code matches; a determining unit that determines whether the detected metadata codes match; a specifying unit that, by referring to a conversion rule and based on the determination result at the determining unit, specifies the data converting function, according to the combination of the metadata codes for the conversion source and for the conversion destination; and a converting unit that uses the specified data converting function to convert the data of the conversion source to have a property prescribed by metadata for the conversion destination.

Data converting apparatus, method, and computer product

The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders.

Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders

The present invention relates to a pyrimidine derivative of the formula (I) and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The pyrimidine derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis. 

Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2

The present invention relates to an imidazo[1,2-c]pyrimidinylacetic acid derivative and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.

Imidazo[1,2-C]pyrimidinylacetic acid derivatives

Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders

4-aryl pyrimidine compounds of general formula and salts thereof: wherein X is CH or N; R1 is hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, etc.; R2 is hydrogen or hydroxy; R3 is hydrogen, C1-6 alkyl, etc.; R4 is hydrogen, hydroxy, halogen, amino, etc.; R5 is hydroxy, amino, carboxy, etc.; R6 is hydrogen, carbamoyl, cyano, carboxy, C1-6 alkoxycarbonyl, etc. and R7 is amino or C1-6 alkanoylamino. The compounds (I) or the salts thereof have an excellent anti-inflammatory activity and the like.

4-6-diphenyl pyridine derivatives as antiinflammatory agents

An optically active (&#x2212;)-7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-5-[(3S)-3-piperidinyl]-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one of the formula (I) or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity 

Optically active pyridine derivative and a medicament containing the same

Pyridine compounds of general formula:wherein &#x2014;Rrepresentsin which Ris hydrogen, Calkyl, halogen, hydroxy, Calkoxy, nitro, amino, Calkylsulfonylamino, Calkoxycarbonyl, Calkylamino, di (Calkyl)amino, Calkanoylamino, phenyl Calkylamino, phenylsulfonylamino, or &#x2014;O&#x2014;(CH)&#x2014;R; Rrepresents hydrogen or halogen; Rrepresents 1.2.3.6-tetrahydro-pyridine, or &#x2014;CRRRwherein Rrepresents H or Calkyl and Rand Rare joined to form a 5-8 membered saturated ring optionally containing up to three heteroatoms; Ris carbamoyl, CN, carboxyl, etc.; Ris amino, Calkylamino, di Calkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.

Pyridine derivatives

Growing community of inventors

Saitama, Japan

Takashi Yoshino